Dynavax Technologies Corporation, a US-based commercial stage biopharmaceutical company, is primarily engaged in developing and commercializing vaccines. Among its product lineup is HEPLISAV-B, an effective hepatitis B vaccine that prevents instances of infection caused by all known subtypes of the hepatitis B virus, aimed at individuals aged 18 years and older in the United States and Europe. The biopharmaceutical company also carries a product called CpG 1018, which is an adjuvant that is integral to the effectiveness of HEPLISAV-B. The company enjoys strategic collaborations with firms like Valneva Scotland Limited, Zhejiang Clover Biopharmaceuticals, Clover Biopharmaceuticals (Hong Kong) Co., Biological E. Limited, PT Bio Farma, Medigen Vaccine Biologics, and Serum Institute of India Pvt. Ltd. Dynavax Technologies Corporation was formerly known as Double Helix Corporation before rebranding to its current name in September 1996. Having been established in 1996, the company is headquartered in Emeryville, California.
Dynavax's ticker is DVAX
The company's shares trade on the NASDAQ stock exchange
They are based in Berkeley, California
There are 201-500 employees working at Dynavax
It is dynavax.com
Dynavax is in the Healthcare sector
Dynavax is in the Drug Manufacturers - Other industry
The following five companies are Dynavax's industry peers: